Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy

Background: No published studies have specifically assessed whether treatment modifications to androgen deprivation therapy (ADT) for prostate cancer (PCa) are frequently carried out in routine clinical practice. The current study was conducted to determine what proportion of patients who had initiated hormone therapy with a gonadotropin-releasing hormone (GnRH) analogue then had their treatment regimen modified during the first 24 months. Methods: A prospective, noninterventional study was carried out in routine clinical practice in France. Patients with locally advanced or metastatic PCa were followed up for 2 years after treatment initiation with a GnRH analogue. The primary endpoint was the proportion of patients with a modification to their initial hormone therapy. Results: In total, 1301 patients were enrolled into the study by 204 physicians, and the primary endpoint could be evaluated for 891 patients. The GnRH analogue treatment was initiated for metastatic PCa (24.2%), locally advanced PCa without planned local treatment (20.6%), locally advanced PCa in association with radiotherapy (31.6%), and biochemical recurrence after local treatment (21.4%). Hormonal treatment was modified in 43.8% (390/891) of patients during the 24-month follow-up period after GnRH analogue initiation. In 61.3% of cases (239/390), the type of modification involved a change of GnRH analogue formulation or switch to another GnRH analogue. A total of five significant predictive factors for GnRH analogue treatment modification were identified: metastatic stage; physician sector; physician speciality; presence or absence of urinary symptoms; and intermittent versus continuous ADT. Conclusions: This study shows that in 43.8% of the patients with advanced PCa, ADT is modified in the first 2 years after initiation in routine clinical practice. Predictive factors for alteration of ADT were metastatic stage and the choice of an intermittent schedule.

[1]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[2]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[3]  M. Hupe,et al.  An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer , 2016, Advances in Therapy.

[4]  I. Thompson,et al.  Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. , 2016, JAMA oncology.

[5]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[6]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[7]  M. Parmar,et al.  20LBA What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses , 2015 .

[8]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[9]  T. Gil,et al.  A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer , 2015, Therapeutic advances in urology.

[10]  Matthew R. Sydes,et al.  Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Kliment,et al.  Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. , 2014, European urology.

[12]  S. Culine,et al.  Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study , 2014, Therapeutic advances in urology.

[13]  E. Vicaut,et al.  Prostate cancer outcomes in France: treatments, adverse effects and two-year mortality , 2014, BMC Urology.

[14]  S. Culine,et al.  Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study , 2014, The aging male : the official journal of the International Society for the Study of the Aging Male.

[15]  C. Pfister,et al.  Recommandations de bonnes pratiques cliniques 2013 du CCAFU: Diagnostic, traitement et suivi des cancers urologiques chez l’homme et la femme , 2013 .

[16]  L. Salomon,et al.  [CCAFU Recommendations 2013: Prostate cancer]. , 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[17]  J. Patard,et al.  [CCAFU Recommendations 2013: Diagnosis, treatment, follow up of urological cancers]. , 2013, Progrès en urologie (Paris).

[18]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.

[19]  N. Bossard,et al.  Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2012 : étude à partir des registres des cancers du réseau Francim. Partie 1 - Tumeurs solides , 2013 .

[20]  A. Bono,et al.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. , 2009, European urology.

[21]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[22]  Has,et al.  Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique , 2008, Oncologie.

[23]  U. Steiner,et al.  Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer , 2007 .

[24]  U. Tunn,et al.  600: Intermittent Androgen Deprivation in Patients with PSA-Relapse after Radical Prostatectomy - Final Results of a European Randomized Prospective Phase-III Clinical Trial Auo Study AP 06/95, EC 507 , 2007 .

[25]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Nicholas Bruchovsky,et al.  Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer , 2006, Cancer.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.